atezolizumab,bevacizumab,paclitaxel,carboplatin
roche
['nsclc', 'sclc', 'impower,150']
rina hui discusses the role of io in egfr+ nsclc. impower150 shows a signal but is it enough? not in my books...
we eagerly await the results of phase 3 trials.
furthermore, there is added tox of egfr therapy after io, so it could complicate any novel tx
#egfr #esmo2022 
Enjoying oncology, without meaning to sound too cynical